Cyxone’s cyclotides recognized as a potential immunomudulating therapeutics for autoimmune diseases
Cyxone announced today that the company’s immunomodulating cyclotide drug, T20K, and its development potential have been recognized in the renowned journal International Journal of Peptide research and Therapeutics. The published scientific article describes the distinct properties of the natural plant protein cyclotides and its demonstrated potential as promising therapeutics in immunopharmacological applications, for example as a treatment for autoimmune diseases.
The two discoverers of immunomodulating cyclotides, Carsten Gründemann and Christian W. Gruber, as well as Kjell G. Stenberg, CEO of Cyxone, show in their research significant therapeutic and prophylactic effects of T20K in a well-proven animal model for multiple sclerosis (MS) after oral administration. In their results, they describe that the clinical symptom of the disease was reduced and occurred later in the studies.
“By being accepted for publication in a reputable scientific journal, we reach researchers who are actively looking for new collaborations or potential partnerships, for example. These people do not always attend conferences or meetings, so with an article with demonstrated results, we can significantly increase our visibility in the right circles,” said Kjell G. Stenberg, CEO of Cyxone. “Cyclotides have the potential to become a new class of therapeutics since it is a completely new substance type, a natural plant protein. This means that our intent is to offer a new tablet formulation that can slow the MS progression, which at the same time produces low side effects so that the treatment can be taken throughout life. This cannot be offered by today’s existing treatments.”
Cyxone’s drug candidate T20K for MS is now undergoing pre-clinical studies, and preparations for the application to the medicines authority for a phase 1 clinical trial such as a long toxicology study and pharmacological dosing study will soon be initiated. As according to the timetable, a study in humans will begin in 2018. In the long term, the company is also planning to investigate the cyclotide’s effect on other autoimmune diseases as the technology has the potential to create new drugs with beneficial pharmacological effects on diseases that today lack effective and safe treatments.
Publication: Gründemann, C., Stenberg, K.G. & Gruber, C.W. Int J Pept Res Ther (2018). https://doi.org/10.1007/s10989-018-9701-1
Contact
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21
221 22 Malmö
Sweden
www.cyxone.com
Forward-looking statement
This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their very nature, similar to research and development activities in biotechnology area, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.
About Cyxone
Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of substances that inhibit key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone’s Certified Adviser on the Nasdaq First North is Erik Penser Bank, +46 (0)8 4638000.
Tags: